TrialCancer2020
A randomized phase 2 trial of pembrolizumab versus pembrolizumab and acalabrutinib in patients with platinum-resistant metastatic urothelial cancer.
Tian Zhang et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.
25 papers cite it
this paperpooled ittrialcites it